Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Michael B Atkins, Georgetown Lombardi Comprehensive Cancer Center
  • ,
  • Brian I Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
  • ,
  • Robert J Motzer, Memorial Sloan-Kettering Cancer Center
  • ,
  • Thomas Powles, Queen Mary University of London
  • ,
  • David F McDermott, Beth Israel Deaconess Medical Center
  • ,
  • Cristina Suarez, Vall d'Hebron Institute of Oncology
  • ,
  • Sergio Bracarda, Azienda Ospedaliera Santa Maria
  • ,
  • Walter M Stadler, The University of Chicago Medical Center
  • ,
  • Frede Donskov
  • Howard Gurney, Macquarie University
  • ,
  • Stephane Oudard, University Paris Descartes, Paris
  • ,
  • Motohide Uemura, Osaka University Graduate School of Medicine
  • ,
  • Elaine T Lam, Anschutz Medical Campus, University of Colorado Cancer Center, Colorado, USA
  • ,
  • Carsten Grüllich, National Center for Tumor Diseases (NCT)
  • ,
  • Caroleen Quach, Genentech Inc., South San Francisco, California, USA.
  • ,
  • Susheela Carroll, Genentech Inc., South San Francisco, California, USA.
  • ,
  • Beiying Ding, Genentech Inc., South San Francisco, California, USA.
  • ,
  • Qian Cindy Zhu, Genentech Inc., South San Francisco, California, USA.
  • ,
  • Elisabeth Piault-Louis, Genentech Inc., South San Francisco, California, USA.
  • ,
  • Christina Schiff, Genentech Inc., South San Francisco, California, USA.
  • ,
  • Bernard Escudier, Institut Gustave Roussy, Villejuif, France.

PURPOSE: Patient-reported outcomes (PRO) were evaluated in the phase III IMmotion151 trial (NCT02420821) to inform overall treatment/disease burden of atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (mRCC).

PATIENTS AND METHODS: Patients were randomized 1:1 to receive atezolizumab 1,200 mg intravenous (i.v.) infusions every 3 weeks (q3w) plus bevacizumab 15 mg/kg i.v. q3w or sunitinib 50 mg per day orally 4 weeks on/2 weeks off. Patients completed the MD Anderson Symptom Inventory (MDASI), National Comprehensive Cancer Network Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19), and Brief Fatigue Inventory (BFI) at baseline, q3w during treatment, at end of treatment, and during survival follow-up. Longitudinal and time to deterioration (TTD) analyses for core and RCC symptoms and their interference with daily life, treatment side-effect bother, and health-related quality of life (HRQOL) were evaluated.

RESULTS: The intent-to-treat population included 454 and 461 patients in the atezolizumab plus bevacizumab and sunitinib arms, respectively. Completion rates for each instrument were 83% to 86% at baseline and ≥ 70% through week 54. Milder symptoms, less symptom interference and treatment side-effect bother, and better HRQOL at most visits were reported with atezolizumab plus bevacizumab versus sunitinib. The TTD HR (95% CI) favored atezolizumab plus bevacizumab for core (HR, 0.50; 0.40-0.62) and RCC symptoms (HR, 0.45; 0.37-0.55), symptom interference (HR, 0.56; 0.46-0.68), and HRQOL (HR, 0.68; 0.58-0.81).

CONCLUSIONS: PROs in IMmotion151 suggest lower overall treatment burden with atezolizumab plus bevacizumab compared with sunitinib in patients with treatment-naïve mRCC and provide further evidence for clinical benefit of this regimen.

OriginalsprogEngelsk
TidsskriftClinical Cancer Research
Vol/bind26
Nummer11
Sider (fra-til)2506-2514
Antal sider9
ISSN1078-0432
DOI
StatusUdgivet - jun. 2020

Bibliografisk note

©2020 American Association for Cancer Research.

Se relationer på Aarhus Universitet Citationsformater

ID: 189784467